Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
ST Renfu: Injection of Micafungin Sodium Approved by the U.S. FDA
ST Pharm announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., has received the approval number from the U.S. Food and Drug Administration for injectable micafungin sodium. This drug has been approved for the treatment of candidemia, acute disseminated candidiasis, candidal peritonitis, and abscesses in adults and pediatric patients aged 4 months and older. Yichang Humanwell submitted the market authorization application to the U.S. FDA in September 2024, with a total R&D investment of approximately 6.8 million RMB for this project. According to IQVIA data, the annual sales of injectable micafungin sodium in the U.S. market are projected to be around 67 million USD in 2024.